 Especially in terms of pro-assessment and health-related quality of life assessment, there are not as many standards established as yet as it goes for other endpoints, for example mobility, mortality etc. So raising the awareness that we need standards and to make definitions and agreements on how to interpret these data will greatly help us in doing the assessment that we do. Well as I said, if we do an assessment we not only look at mortality, mobility and adverse events but health-related quality of life is by its own an endpoint of interest. So if we have standards which increase the quality of these data and the analysis that greatly helps us in doing the assessments as quality of life is a central part in our assessment and has ever been. The thing is if we have clear recommendation, we have clear standards that also we can apply to. We obviously have to refer to the state of the art of the evidence basements. So the better the standards are, the better that is for ourselves to have a guideline on how to do our projects and how to do our assessments. We believe that health-related quality of life data are very important to assess a drug from a patient perspective point of view, although a patient representative might argue on that better than I can. But we think that is really an aspect which has not been looked into in the past as much as was needed or as much as would have been deserved and we're happy that this initiative can provide or can can stress the importance of these endpoints and we're happy we can contribute to that as well.